Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5172272
Max Phase: Preclinical
Molecular Formula: C48H69N13O8
Molecular Weight: 956.16
Associated Items:
ID: ALA5172272
Max Phase: Preclinical
Molecular Formula: C48H69N13O8
Molecular Weight: 956.16
Associated Items:
Canonical SMILES: CCCC[C@H](N)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)N(C)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCN2C1=O
Standard InChI: InChI=1S/C48H69N13O8/c1-3-4-17-32(49)42(64)59-37-27-40(62)53-22-11-10-19-34(41(50)63)56-45(67)39(26-30-28-55-33-18-9-8-16-31(30)33)60(2)46(68)35(20-12-23-54-48(51)52)57-43(65)36(25-29-14-6-5-7-15-29)58-44(66)38-21-13-24-61(38)47(37)69/h5-9,14-16,18,28,32,34-39,55H,3-4,10-13,17,19-27,49H2,1-2H3,(H2,50,63)(H,53,62)(H,56,67)(H,57,65)(H,58,66)(H,59,64)(H4,51,52,54)/t32-,34-,35-,36+,37-,38-,39-/m0/s1
Standard InChI Key: UIKNVPAJAICFKL-YIZWONDUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 956.16 | Molecular Weight (Monoisotopic): 955.5392 | AlogP: -0.33 | #Rotatable Bonds: 14 |
Polar Surface Area: 332.92 | Molecular Species: BASE | HBA: 10 | HBD: 11 |
#RO5 Violations: 2 | HBA (Lipinski): 21 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.78 | CX Basic pKa: 11.54 | CX LogP: -1.70 | CX LogD: -4.15 |
Aromatic Rings: 3 | Heavy Atoms: 69 | QED Weighted: 0.06 | Np Likeness Score: 0.65 |
1. Gimenez LE, Noblin TA, Williams SY, Mullick Bagchi S, Ji RL, Tao YX, Jeppesen CB, Conde-Frieboes KW, Sawyer TK, Grieco P, Cone RD.. (2022) Demonstration of a Common DPhe7 to DNal(2')7 Peptide Ligand Antagonist Switch for Melanocortin-3 and Melanocortin-4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of Melanocortin Peptides., 65 (8.0): [PMID:35404053] [10.1021/acs.jmedchem.1c01295] |
Source(1):